[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:il13ra2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"IL13RA2 Gene",4,3,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07544992","Locoregional Administration of Genetically Engineered Cells (EGFR\u002FIL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas",[12],"Phase 1","RECRUITING","2026-08-26T02:15:22.311223Z","2026-07-05T05:32:16.686026Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04510051","CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children",[12],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:26.913310Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06815029","Intracranial Genetically Modified Immune Cells (TGFβR2KO\u002FIL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma",[12],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:26.691788Z",{"nct_id":29,"title":30,"phases":31,"status":32,"updated_at":33,"content_modified":34},"NCT04003649","IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T01:58:27.073747Z","2026-05-05T02:35:31.932809Z"]